ArticleFrontiers in medicine2025
Efficacy of belimumab on extra-renal lupus in patients with lupus nephritis and end-stage renal disease.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), with approximately 20-30% of LN patients progressing to end-stage renal disease (ESRD) within a decade. Persistent extra-renal SLE activity, cardiovascular events, and infections significantly contribute to adverse outcomes. Current therapeutic strategies primarily rely on glucocorticoids and immunosuppressants; however, the adverse effects of these agents are intensified in ESRD patients. Belimumab, a B-lymphocyte-targeted biologic agent, has demonstrated efficacy in managing SLE but lacks sufficient data regarding its application in ESRD-LN patients. This study aims to evaluate the role of belimumab in controlling extra-renal disease activity, optimizing medication use, and assessing safety in ESRD-LN patients. Methods: This retrospective analysis involved eight LN patients with ESRD (eGFR <15 mL/min/1.73 m Results: This study analyzed data from eight ESRD-LN patients treated with belimumab over a median follow-up period of 28.01 ± 14.57 months. Belimumab significantly reduced extra-renal SLEDAI scores (from 6.13 ± 3.09 to 1.50 ± 1.41, Conclusion: Belimumab appears to be a promising therapeutic option for ESRD-LN patients, effectively controlling extra-renal disease activity, reducing glucocorticoid use, and demonstrating a favorable safety profile. Further research is required to optimize dosing strategies and to validate the long-term efficacy and safety of belimumab in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.